Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Staphylococcus Aureus Infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    71 result(s) found for: Staphylococcus Aureus Infection. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-000577-77 Sponsor Protocol Number: Uni-Koeln-1400 Start Date*: 2013-07-11
    Sponsor Name:University of Düsseldorf
    Full Title: EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options)
    Medical condition: Low risk Staphylococcus aureus bloodstream infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10041943 Staphylococcus aureus septicaemia LLT
    19.0 100000004862 10054638 Staphylococcus aureus septicemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000344-10 Sponsor Protocol Number: Start Date*: 2012-05-24
    Sponsor Name:Medical Research Council [...]
    1. Medical Research Council
    2. Kings College London
    Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial
    Medical condition: S. aureus bacteraemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.1 10021881 - Infections and infestations 10054638 Staphylococcus aureus septicemia LLT
    14.1 10021881 - Infections and infestations 10058863 Staphylococcus aureus bacteraemia LLT
    14.1 10021881 - Infections and infestations 10041943 Staphylococcus aureus septicaemia LLT
    14.1 10021881 - Infections and infestations 10058867 Methicillin-resistant staphylococcal aureus sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001097-34 Sponsor Protocol Number: CD-ID-MEDI4893-1139 Start Date*: 2014-09-08
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha To...
    Medical condition: Prevention of Staphyloccus aureus pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10041942 Staphylococcus aureus pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GR (Completed) DE (Completed) ES (Completed) CZ (Completed) PT (Completed) HU (Completed) GB (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004018-15 Sponsor Protocol Number: V710-003 Start Date*: 2008-01-17
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult P...
    Medical condition: Staphylococcus aureus bacteremia Staphylococcus aureus mediastinitis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    14.0 10021881 - Infections and infestations 10066413 Staphylococcus aureus mediastinitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) AT (Completed) FR (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003059-31 Sponsor Protocol Number: CF-301-102 Start Date*: 2017-11-02
    Sponsor Name:ContraFect Corporation
    Full Title: A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy fo...
    Medical condition: S. aureus bloodstream infections
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014665 Endocarditis PT
    20.0 10021881 - Infections and infestations 10077008 Methicillin-sensitive Staphylococcus aureus infection LLT
    20.1 10021881 - Infections and infestations 10003997 Bacteraemia PT
    20.1 10021881 - Infections and infestations 10041937 Staphylococcus aureus endocarditis LLT
    20.0 10021881 - Infections and infestations 10021839 Infection MRSA LLT
    20.0 10021881 - Infections and infestations 10054637 Staphylococcal bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) GR (Completed) GB (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000005-12 Sponsor Protocol Number: CRCFC-TEICO.SA.2022 Start Date*: 2024-02-21
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in CYSTIC FIBROSIS PATIENTS
    Medical condition: cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    20.0 100000004862 10075981 Staphylococcus aureus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003529-13 Sponsor Protocol Number: 010617 Start Date*: 2017-10-19
    Sponsor Name:Thomas Benfield
    Full Title: Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia: A randomized, non-blinded, non-inferiority interventional study
    Medical condition: Staphylococcus aureus bacteremia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004469-11 Sponsor Protocol Number: PP-SA-001 Start Date*: 2022-01-11
    Sponsor Name:PHERECYDES PHARMA
    Full Title: PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus ...
    Medical condition: knee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003510-25 Sponsor Protocol Number: 2014-PT029 Start Date*: 2016-01-25
    Sponsor Name:XBiotech USA, Inc.
    Full Title: A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized with Bacteremia Due to Staphylococcus Aureus
    Medical condition: Staphylococcus aereus Bacteremia
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004044-28 Sponsor Protocol Number: AKF-396 Start Date*: 2020-12-18
    Sponsor Name:University of Southern Denmark
    Full Title: Flucloxacillin as an inducer of CYP-enzymes
    Medical condition: Healthy volunteers. (Flucloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by flucloxacillin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003814-37 Sponsor Protocol Number: AKF-400 Start Date*: 2021-11-29
    Sponsor Name:Odense University Hosipital
    Full Title: The effect of dicloxacillin on oral absorption of drugs
    Medical condition: Healthy volunteers. (Dicloxacillin is used against infections caused by beta-lactamase-producing organisms) Testing for drug-drug interactions caused by dicloxacillin.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-004863-29 Sponsor Protocol Number: 1M Start Date*: 2013-02-18
    Sponsor Name:University Hospitals Leuven (Gasthuisberg) [...]
    1. University Hospitals Leuven (Gasthuisberg)
    2. agentschap innoveren en ondernemen
    Full Title: Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility st...
    Medical condition: staphylococcus aureus bacteraemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000586-37 Sponsor Protocol Number: BACSARM Start Date*: 2013-09-23
    Sponsor Name:Miquel Pujol Rojo (Infectious Diseases Service-Hospital Universitari de Bellvitge-IDIBELL)
    Full Title: Randomized multicenter study to assess efficacy of Daptomycin plus Fosfomycin versus Daptomycin monotherapy for treatment of methicillin resistant Staphylococcus aureus bacteremia in hospitalized p...
    Medical condition: Methicillin resistant Staphylococcus aureus bacteremia, complicated or uncomplicated
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004372-27 Sponsor Protocol Number: 0112 Start Date*: 2016-05-17
    Sponsor Name:Theravance Biopharma Ireland Limited
    Full Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infectiv...
    Medical condition: Staphylococcus aureus Bacteremia Including Infective Endocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) LV (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002644-40 Sponsor Protocol Number: B3451002 Start Date*: 2015-05-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (SA4Ag) in Adults Undergoing Elective Posterior Instrum...
    Medical condition: Prophylaxis for prevention of Post-operative S. aureus infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    17.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) HU (Completed) AT (Prematurely Ended) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024042-30 Sponsor Protocol Number: DUR001-301 Start Date*: 2012-05-04
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKI...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004921-25 Sponsor Protocol Number: 848018006 Start Date*: 2020-08-17
    Sponsor Name:Amsterdam UMC
    Full Title: Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia
    Medical condition: Unnecessary long-term exposure to antibiotics can cause adverse events such as renal and hepatic toxicity, health-care-related infections and antibiotic resistance. Staphylococcus aureus bacteremia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002130-40 Sponsor Protocol Number: DUR001-302 Start Date*: 2011-11-23
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SK...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004339-35 Sponsor Protocol Number: AR-301-002 Start Date*: 2019-01-16
    Sponsor Name:Aridis Pharmaceuticals, Inc.
    Full Title: A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) c...
    Medical condition: Staphylococcus aureus pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10035734 Pneumonia staphylococcal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FR (Completed) LV (Completed) BE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001699-43 Sponsor Protocol Number: BPR-CS-009 Start Date*: 2018-12-13
    Sponsor Name:Basilea Pharmaceutica International Ltd
    Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ...
    Medical condition: Complicated staphylococcus aureus bacteremia (cSAB)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10058887 Staphylococcus aureus bacteremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:53:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA